Biotest

Biotest Equity

Delisted

The The Equity of Biotest (BIO.DE) as of Nov 19, 2026 is 530.70 M EUR. In the previous year, The Equity was 498.90 M EUR — a change of 6.37% (higher).

Equity

530.70 MEUR

YoY

6.37%

Last updated:

In 2024, Biotest's equity was 530.70 M EUR, a 6.37% increase from the 498.90 M EUR equity in the previous year.

The Biotest Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
347.60 M EUR
Jan 1, 2018
495.00 M EUR
Jan 1, 2019
476.90 M EUR
Jan 1, 2020
441.60 M EUR
Jan 1, 2021
380.40 M EUR
Jan 1, 2022
371.10 M EUR
Jan 1, 2023
498.90 M EUR
Jan 1, 2024
530.70 M EUR
The Biotest Equity history
YEAREquityYoY
530.70 MEUR+6.37%
498.90 MEUR+34.44%
371.10 MEUR-2.44%
380.40 MEUR-13.86%
441.60 MEUR-7.40%
476.90 MEUR-3.66%
495.00 MEUR+42.41%
347.60 MEUR-3.58%
360.50 MEUR-12.54%
412.20 MEUR-14.14%
480.10 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biotest's Equity

Biotest's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biotest's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biotest's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biotest's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biotest’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biotest stock

The Equity of Biotest is 530.70 M EUR in 2024.

The Equity of Biotest changed from 498.90 M EUR to 530.70 M EUR, representing a 6.37% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Biotest since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Biotest historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biotest

All Key Metrics — Biotest